COVID-19
Regístrese
metricas
covid
Clínica e Investigación en Arteriosclerosis (English Edition)
Suscribe to the journal
Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Consensus document on the management of the atherogenic dyslipidaemia of the Spa...
Journal Information
Back to article

Statistics

Follow this link to access the full text of the article

Consensus statement
Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis
Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis
Juan F. Ascasoa,
Corresponding author
ascaso@uv.es

Corresponding author.
, Jesús Millánb, Antonio Hernández-Mijaresc, Mariano Blascod, Ángel Breae, Ángel Díazf, Teresa Mantillag, Juan Pedro-Boteth, Xavier Pintói, Working Group on Atherogenic Dyslipemia of the EAS
a Servicio de Endocrinología y Nutrición, CIBERDEM, Hospital Clínico Universitario de Valencia, INCLIVA, Universitat de Valencia, Valencia, Spain
b Unidad de Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain
c Servicio de Endocrinología y Nutrición, Hospital Universitario Dr. Peset-FISABIO, Departamento de Medicina, Universidad de Valencia, Valencia, Spain
d C.S. Delicias Sur, Área Sanitaria III, Zaragoza, Spain
e Unidad de Lípidos, Servicio de Medicina Interna, Hospital San Pedro, Logroño, Spain
f Centro de Salud de Bembire, Universidad de León, Membibre, León, Spain
g Centro de Salud Universitario Prosperidad, Universidad Autónoma de Madrid, Madrid, Spain
h Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain
i Servicio de Medicina Interna, Hospital de Bellvitge, CIBERobn, Fipec, Universidad de Barcelona, Idibell, Hospitalet de Llobregat, Barcelona, Spain
Ver más
Read
1022
Times
was read the article
271
Total PDF
751
Total HTML
Share statistics
 array:23 [
  "pii" => "S2529912317000183"
  "issn" => "25299123"
  "doi" => "10.1016/j.artere.2016.11.001"
  "estado" => "S300"
  "fechaPublicacion" => "2017-03-01"
  "aid" => "389"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Clin Investig Arterioscler. 2017;29:86-91"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 27
    "formatos" => array:2 [
      "HTML" => 26
      "PDF" => 1
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S021491681630170X"
      "issn" => "02149168"
      "doi" => "10.1016/j.arteri.2016.11.001"
      "estado" => "S300"
      "fechaPublicacion" => "2017-03-01"
      "aid" => "389"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "pgl"
      "cita" => "Clin Invest Arterioscl. 2017;29:86-91"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 1663
        "formatos" => array:3 [
          "EPUB" => 19
          "HTML" => 1184
          "PDF" => 460
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Documento de consenso</span>"
        "titulo" => "Documento de consenso sobre el manejo de la dislipemia aterog&#233;nica de la Sociedad Espa&#241;ola de Arteriosclerosis"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "86"
            "paginaFinal" => "91"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1455
                "Ancho" => 2802
                "Tamanyo" => 180899
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algoritmo del tratamiento de la dislipemia aterog&#233;nica&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">c-no-HDL&#58; colesterol no HDL &#40;colesterol total menos colesterol HDL&#41;&#59; cHDL&#58; colesterol de las lipoprote&#237;nas de alta densidad&#59; CV&#58; cardiovascular&#59; TG&#58; triglic&#233;ridos&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Juan F&#46; Ascaso, Jes&#250;s Mill&#225;n, Antonio Hern&#225;ndez-Mijares, Mariano Blasco, &#193;ngel Brea, &#193;ngel D&#237;az, Teresa Mantilla, Juan Pedro-Botet, Xavier Pint&#243;"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Juan F&#46;"
                "apellidos" => "Ascaso"
              ]
              1 => array:2 [
                "nombre" => "Jes&#250;s"
                "apellidos" => "Mill&#225;n"
              ]
              2 => array:2 [
                "nombre" => "Antonio"
                "apellidos" => "Hern&#225;ndez-Mijares"
              ]
              3 => array:2 [
                "nombre" => "Mariano"
                "apellidos" => "Blasco"
              ]
              4 => array:2 [
                "nombre" => "&#193;ngel"
                "apellidos" => "Brea"
              ]
              5 => array:2 [
                "nombre" => "&#193;ngel"
                "apellidos" => "D&#237;az"
              ]
              6 => array:2 [
                "nombre" => "Teresa"
                "apellidos" => "Mantilla"
              ]
              7 => array:2 [
                "nombre" => "Juan"
                "apellidos" => "Pedro-Botet"
              ]
              8 => array:2 [
                "nombre" => "Xavier"
                "apellidos" => "Pint&#243;"
              ]
              9 => array:1 [
                "colaborador" => "Grupo de trabajo sobre Dislipemia Aterog&#233;nica de la SEA"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2529912317000183"
          "doi" => "10.1016/j.artere.2016.11.001"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912317000183?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021491681630170X?idApp=UINPBA00004N"
      "url" => "/02149168/0000002900000002/v2_201706011708/S021491681630170X/v2_201706011708/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2529912317000213"
    "issn" => "25299123"
    "doi" => "10.1016/j.artere.2017.03.003"
    "estado" => "S300"
    "fechaPublicacion" => "2017-03-01"
    "aid" => "365"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Clin Investig Arterioscler. 2017;29:92-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 20
      "HTML" => 20
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
      "titulo" => "Mitochondrial dysfunction associated with nitric oxide pathways in glutamate neurotoxicity"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "92"
          "paginaFinal" => "97"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Disfunci&#243;n mitocondrial asociada a las v&#237;as del &#243;xido n&#237;trico en la neurotoxicidad por glutamato"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Walter Manucha"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Walter"
              "apellidos" => "Manucha"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0214916816300286"
        "doi" => "10.1016/j.arteri.2016.04.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916816300286?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912317000213?idApp=UINPBA00004N"
    "url" => "/25299123/0000002900000002/v1_201704010059/S2529912317000213/v1_201704010059/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2529912317000171"
    "issn" => "25299123"
    "doi" => "10.1016/j.artere.2017.02.001"
    "estado" => "S300"
    "fechaPublicacion" => "2017-03-01"
    "aid" => "401"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Clin Investig Arterioscler. 2017;29:67-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 9
      "formatos" => array:2 [
        "HTML" => 8
        "PDF" => 1
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "HSP90 inhibitors as a future therapeutic strategy in diabetes-driven atherosclerosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "67"
          "paginaFinal" => "68"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Inhibidores de HSP90 como futura estrategia terap&#233;utica en la aterosclerosis asociada a diabetes"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Manuel V&#225;zquez-Carrera"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "V&#225;zquez-Carrera"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0214916817300268"
        "doi" => "10.1016/j.arteri.2017.02.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916817300268?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912317000171?idApp=UINPBA00004N"
    "url" => "/25299123/0000002900000002/v1_201704010059/S2529912317000171/v1_201704010059/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>"
    "titulo" => "Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "86"
        "paginaFinal" => "91"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Juan F&#46; Ascaso, Jes&#250;s Mill&#225;n, Antonio Hern&#225;ndez-Mijares, Mariano Blasco, &#193;ngel Brea, &#193;ngel D&#237;az, Teresa Mantilla, Juan Pedro-Botet, Xavier Pint&#243;"
        "autores" => array:10 [
          0 => array:4 [
            "nombre" => "Juan F&#46;"
            "apellidos" => "Ascaso"
            "email" => array:1 [
              0 => "ascaso&#64;uv&#46;es"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Jes&#250;s"
            "apellidos" => "Mill&#225;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Antonio"
            "apellidos" => "Hern&#225;ndez-Mijares"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mariano"
            "apellidos" => "Blasco"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "&#193;ngel"
            "apellidos" => "Brea"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "&#193;ngel"
            "apellidos" => "D&#237;az"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Teresa"
            "apellidos" => "Mantilla"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Juan"
            "apellidos" => "Pedro-Botet"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Xavier"
            "apellidos" => "Pint&#243;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          9 => array:1 [
            "colaborador" => "Working Group on Atherogenic Dyslipemia of the EAS"
          ]
        ]
        "afiliaciones" => array:9 [
          0 => array:3 [
            "entidad" => "Servicio de Endocrinolog&#237;a y Nutrici&#243;n&#44; CIBERDEM&#44; Hospital Cl&#237;nico Universitario de Valencia&#44; INCLIVA&#44; Universitat de Valencia&#44; Valencia&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Unidad de L&#237;pidos&#44; Servicio de Medicina Interna&#44; Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Facultad de Medicina&#44; Universidad Complutense&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Endocrinolog&#237;a y Nutrici&#243;n&#44; Hospital Universitario Dr&#46; Peset-FISABIO&#44; Departamento de Medicina&#44; Universidad de Valencia&#44; Valencia&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "C&#46;S&#46; Delicias Sur&#44; &#193;rea Sanitaria III&#44; Zaragoza&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Unidad de L&#237;pidos&#44; Servicio de Medicina Interna&#44; Hospital San Pedro&#44; Logro&#241;o&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Centro de Salud de Bembire&#44; Universidad de Le&#243;n&#44; Membibre&#44; Le&#243;n&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Centro de Salud Universitario Prosperidad&#44; Universidad Aut&#243;noma de Madrid&#44; Madrid&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Unidad de L&#237;pidos y Riesgo Vascular&#44; Servicio de Endocrinolog&#237;a y Nutrici&#243;n&#44; Hospital del Mar&#44; Universitat Aut&#242;noma de Barcelona&#44; Barcelona&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Medicina Interna&#44; Hospital de Bellvitge&#44; CIBERobn&#44; Fipec&#44; Universidad de Barcelona&#44; Idibell&#44; Hospitalet de Llobregat&#44; Barcelona&#44; Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Documento de consenso sobre el manejo de la dislipemia aterog&#233;nica de la Sociedad Espa&#241;ola de Arteriosclerosis"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1455
            "Ancho" => 2663
            "Tamanyo" => 176493
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Atherogenic dyslipidaemia treatment algorithm&#46; Non-HDL-C&#58; non-HDL cholesterol &#40;total cholesterol minus HDL cholesterol&#41;&#59; HDL-C&#58; high-density lipoprotein cholesterol&#59; CV&#58; cardiovascular&#59; TG&#58; triglycerides&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Definition of atherogenic dyslipidaemia</span><p id="par0005" class="elsevierStylePara elsevierViewall">Atherogenic dyslipidaemia is characterised by an increase in total plasma triglycerides &#40;TG&#41; and a decrease in high density lipoprotein cholesterol &#40;HDL-C&#41;&#46; Alongside these two lipid disorders which define atherogenic dyslipidaemia we find an increase in TG-rich and apolipoprotein B &#40;apoB&#41; carrier lipoproteins&#46; This is usually a moderate increase and&#44; on occasion&#44; low-density lipoprotein cholesterol &#40;LDL-C&#41; values are close to normal&#44; with predominantly small and dense LDL particles&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Atherogenic dyslipidaemia is hugely important as it is associated with different conditions that are currently very prevalent among the general population&#44; and which represent a high cardiovascular risk&#44; such as overweight &#40;37&#37;&#41;&#44; obesity &#40;17&#37;&#41;&#44; diabetes &#40;14&#37;&#41; and hyperglycaemia&#44; and metabolic syndrome &#40;30&#37;&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">2&#44;3</span></a> Moreover&#44; atherogenic dyslipidaemia is in itself an indicator of high cardiovascular risk among subjects with diabetes&#46; In this sense&#44; atherogenic dyslipidaemia is associated with a higher risk of myocardial ischaemia or silent coronary artery disease in patients with type 2 diabetes and LDL-C levels &#60;130<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">In fact&#44; in the Spanish population&#44; the prevalence of atherogenic dyslipidaemia is elevated&#44; with a presence in 34&#37; of diabetic patients&#44; 21&#37; of high-risk patients with controlled LDL and 21&#8211;34&#37; of patients with a history of any form of vascular disease &#40;coronary&#44; cerebral or peripheral artery&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">5</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Diagnosis</span><p id="par0020" class="elsevierStylePara elsevierViewall">Atherogenic dyslipidaemia is characterised by hypertriglyceridaemia&#44; which is a consequence of an increase in TG-rich lipoproteins&#44; including their remnant particles&#44; and due to the moderate elevation of LDLs&#44; i&#46;e&#46; the group of atherogenic lipoproteins that contain apoB&#46; All of the abovementioned lipoproteins can be quantified using non-HDL cholesterol &#40;non-HDL-C&#41; or apoB concentrations&#46; Conversely&#44; there is a decrease in HDL-C&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">Along with these disorders&#44; the presence of an increase in small and dense LDL particles&#44; calculated indirectly using the TG&#47;HDL-C ratio&#44; and the increase in atherogenic indices&#44; particularly total&#47;HDL cholesterol&#44; constitute the set of findings in this type of dyslipidaemia&#44;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">6</span></a> a summary of which is presented in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Cardiovascular risk and therapeutic targets</span><p id="par0030" class="elsevierStylePara elsevierViewall">Non-HDL-C essentially represents the sum of lipoprotein cholesterol containing apoB&#44; i&#46;e&#46; atherogenic lipoproteins that can be deposited along the arterial wall&#46; As such&#44; in patients with atherogenic cholesterol&#44; it has been recommended that the most suitable therapeutic target is non-HDL-C or apoB&#44; as both parameters have a better correlation with cardiovascular risk than LDL-C&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">7</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Non-HDL-C has proven to be a significant cardiovascular risk factor that can replace apoB in routine practice&#44; as it is more economic&#44; reliable and easier to calculate&#44; since it only requires subtracting the HDL-C from the total cholesterol &#8211; analytical parameters that are available at all healthcare facilities&#8217; clinical laboratories&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">The scientific evidence regarding the association between high LDL-C levels and an increased risk of cardiovascular disease is strong and indisputable&#46; However&#44; even with adequate LDL-C control&#44; a considerable percentage of subjects remain who maintain a high vascular risk attributable to other lipid disorders&#44; such as hypertriglyceridaemia and decreased HDL-C&#46; The greatest cardiovascular risk is found when disorders in these three fractions coexist&#58; LDL-C<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>130<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#44; HDL-C<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>40<span class="elsevierStyleHsp" style=""></span>mg&#47;dl and TG<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">8</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">A meta-analysis by Andersson et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">9</span></a> on 62&#44;154 patients included in 8 studies&#44; showed that non-HDL-C had a better correlation with cardiovascular risk than LDL-C&#59; moreover&#44; the subjects who reached their therapeutic target for LDL-C but not non-HDL-C had a risk increase of 32&#37; compared to those who achieved both targets&#46; Similarly&#44; a recent study has revealed that atheromatous plaque progression was more closely related to non-HDL-C than LDL-C concentrations&#46; Accordingly&#44; the lowest levels of non-HDL-C and TG showed a significant association with plaque regression through the different categories of cardiovascular risk&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">10</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">We can therefore consider that&#44; in patients with atherogenic dyslipidaemia&#44; the main risk predictor&#8212;and thus the primary control target&#8212;is non-HDL-C&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">11</span></a> Furthermore&#44; it has been established that the cardiovascular risk presented by subjects with atherogenic dyslipidaemia is twice or three times that of the general population&#44; and in the majority of cases&#44; they have a high cardiovascular risk&#46;<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">12&#44;13</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">As such&#44; we can consider non-HDL-C as the main therapeutic target in cases of atherogenic dyslipidaemia&#46; The calculation of non-HDL-C based on the total cholesterol minus HDL-C is established as the target according to the cardiovascular risk&#59; its values have been set as those for the target LDL-C plus 30<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">Consequently&#44; the target non-HDL-C will be &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8211;</span><p id="par0065" class="elsevierStylePara elsevierViewall">&#60;145<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in subjects with moderate risk&#44; an unusual situation in clinical practice among cases of atherogenic dyslipidaemia&#44; as these subjects usually present lipid characteristics or an association with other risk factors &#40;abdominal obesity&#44; metabolic syndrome or diabetes&#41; which increase the cardiovascular risk evaluation&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8211;</span><p id="par0070" class="elsevierStylePara elsevierViewall">&#60;130<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in subjects with a high risk&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8211;</span><p id="par0075" class="elsevierStylePara elsevierViewall">&#60;100<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in subjects with a very high risk&#46;</p></li></ul></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">The secondary targets are TG and HDL-C concentrations&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Hypertriglyceridaemia is an independent cardiovascular risk factor and TG levels &#60;150<span class="elsevierStyleHsp" style=""></span>mg&#47;dl<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">14</span></a> are considered optimal&#46; As such&#44; although it has not been clearly established&#44; the therapeutic target may be considered as &#60;150<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">Plasma HDL-C concentrations &#60;40<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in men and &#60;45<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in women are also considered an independent cardiovascular risk factor and&#44; as a result&#44; figures exceeding those mentioned above would be desirable&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">14&#44;15</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Points of consensus in the clinical assessment of atherogenic dyslipidaemia</span><p id="par0095" class="elsevierStylePara elsevierViewall">Based on the available data and the most significant clinical evidence put forth with respect to atherogenic dyslipidaemia-associated cardiovascular risk&#44; the key points are as follows&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8211;</span><p id="par0100" class="elsevierStylePara elsevierViewall">Hypertriglyceridaemia is an independent risk factor that is exacerbated in the presence of elevated LDL-C or low HDL-C levels&#46; It is one of the key aspects of lipid-related residual vascular risk&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8211;</span><p id="par0105" class="elsevierStylePara elsevierViewall">In order to assess overall cardiovascular risk&#44; the determination of TG and HDL-C is fundamental&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8211;</span><p id="par0110" class="elsevierStylePara elsevierViewall">The most practical markers for assessing the risk attributable to atherogenic dyslipidaemia are non-HDL-C &#40;value above the LDL-C concentration&#41; and TG &#40;as a marker of remnant TG-rich lipoproteins&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8211;</span><p id="par0115" class="elsevierStylePara elsevierViewall">Non-HDL-C is the most suitable therapeutic target for controlling cardiovascular risk in patients with atherogenic dyslipidaemia&#46; It has a good correlation with apoB &#40;the ideal marker&#44; but widespread availability for routine employment is lacking&#41;&#44; is easy to calculate&#44; presents no additional cost and has great stability for calculating risk&#46;</p></li></ul></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Treatment of atherogenic dyslipidaemia</span><p id="par0120" class="elsevierStylePara elsevierViewall">Atherogenic dyslipidaemia is a critical element that clearly contributes to the residual risk that remains following treatment with statins&#46; This lipoprotein disorder is under-diagnosed&#44; under-treated and under-controlled&#44; which is particularly relevant in patients with a high cardiovascular risk and those with diabetes&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">16</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">It is necessary to consider the approach to atherogenic dyslipidaemia based on the scientific evidence available in order to improve its treatment and adherence to the same&#46;</p><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Lifestyle changes</span><p id="par0130" class="elsevierStylePara elsevierViewall">The incorporation of a healthy diet&#44; regular physical exercise and smoking cessation are the first measures for reducing cardiovascular risk in all patients&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">The Mediterranean diet&#44; with a reduced calorie intake in case of overweight or abdominal obesity&#44; is accompanied by clear cardiovascular benefits and increased longevity&#46; As well as having beneficial effects on lipid profiles&#44; it has positive effects on hypertension and hyperglycaemia&#46; Alcohol consumption should be moderated or avoided in cases of moderate to severe hypertriglyceridaemia&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Aerobic exercise is also paramount in atherogenic dyslipidaemia and in preventing and treating metabolic syndrome&#44; hyperglycaemia&#44; diabetes and cardiovascular disease&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Pharmacological treatment</span><p id="par0145" class="elsevierStylePara elsevierViewall">Due to the fact that most patients with atherogenic dyslipidaemia have a high or very high risk of developing cardiovascular disease&#44; it is generally necessary to combine lifestyle changes with different lipid-lowering drugs&#46;</p><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Statins</span><p id="par0150" class="elsevierStylePara elsevierViewall">Treatment with statins will be initiated&#44; choosing the type and dose that is necessary to achieve the therapeutic target&#44; keeping in mind that increases in LDL-C and non-HDL-C are usually moderate&#46; The benefits of statin treatment are well known and sufficiently demonstrated&#46; A reduction of 1<span class="elsevierStyleHsp" style=""></span>mmol&#47;l &#40;approximately 39<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&#41; is associated with a 21&#37; reduction in the incidence of serious cardiovascular events and a 23&#37; reduction in coronary events&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">17</span></a> One relevant fact is that 10-year treatment with statins in subjects with a low cardiovascular risk is related to a 23&#37; reduction in non-fatal myocardial infarction events&#44; in the case of low-dose statins&#44; and a 53&#37; reduction with more powerful statins&#44; including a significant reduction in cardiovascular events&#46;<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">18&#44;19</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Fibrates</span><p id="par0155" class="elsevierStylePara elsevierViewall">When the non-HDL-C and LDL-C targets have been achieved through treatment with statins&#44; an unacceptable risk of cardiovascular events still remains due to the presence of the main components of atherogenic dyslipidaemia &#40;hypertriglyceridaemia and decreased HDL-C&#41;&#46; The administration of fibrates in these conditions corrects these lipid disorders and has additional cardiovascular benefits&#46; In case of a contraindication or fibrate intolerance in patients with elevated TG levels&#44; omega-3 fatty acids may prove beneficial&#46;<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">20&#44;21</span></a> Fibrates have proven beneficial in primary and secondary prevention studies&#44; as well as in the diabetic population&#44; fundamentally in subgroups with atherogenic dyslipidaemia or any of its components&#44; with a 28&#8211;30&#37; reduction in cardiovascular events&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Fibrate-induced lipid changes are explained by modifications in the expressivity of various genes involved in lipid metabolism through peroxisome proliferator-activated receptors &#945; &#40;PPAR&#945;&#41;&#44; with reductions in TG and LDL-C of 20&#8211;50&#37; and 5&#8211;20&#37;&#44; respectively&#44; a decrease in small and dense LDL particles&#44; and a HDL-C increase of 5&#8211;20&#37;&#46; These effects are dependent on baseline concentrations<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">11</span></a> and are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#46;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">22</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0165" class="elsevierStylePara elsevierViewall">The safest fibrate to combine with a statin is the fenofibrate&#59; its addition achieves a greater cholesterol-lowering effect and control of non-HDL-C&#44; TG and HDL-C&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Contrary to what happens with gemfibrozil&#44; the combination of fenofibrate and a statin has demonstrated an excellent safety profile in all clinical studies including a large number of patients and a prolonged treatment period&#46; Moreover&#44; the effects of the fenofibrate-statin combination on the elevation of muscle and&#47;or liver enzymes&#44; or on temporary creatinine increases&#44; do not differ from those observed in the monotherapy regimen and the reversibility of the effects is thus demonstrable&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">The main clinical evidence of fibrate treatment is shown in <a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#46;<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">15&#44;23</span></a></p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Extralipid effects of fenofibrate</span><p id="par0180" class="elsevierStylePara elsevierViewall">The results of clinical studies with fenofibrate have suggested&#44; in addition to changes in the lipid profile&#44; other vascular protection actions&#44; such as increased nitric oxide expression and decreased oxidative stress&#46; Fibrates exert an anti-inflammatory action on attenuating the production of inflammatory cytokines&#46; Fenofibrate complements this anti-inflammatory action&#44; significantly reducing levels of C-reactive protein&#44; the CD40 ligand&#44; monocyte chemoattractant protein-1 and the macrophage stimulating factor&#46; It also reduces plasma fibrinogen concentrations by up to 20&#37;&#44; as well as thrombin-antithrombin complexes and plasminogen activator inhibitor-1&#46; Another important extralipid effect is the slowdown of diabetic retinopathy progression&#44; independent of glucose and lipid control&#46; Furthermore&#44; the abovementioned trials suggest that fenofibrate plays a protective role in diabetic nephropathy and neuropathy&#46;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">23</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">Based on these facts&#44; the algorithm in <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a> is established for treating atherogenic dyslipidaemia and controlling the accompanying cardiovascular risk&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Points of consensus in the treatment of atherogenic dyslipidaemia</span><p id="par0190" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">&#8211;</span><p id="par0195" class="elsevierStylePara elsevierViewall">Lifestyle changes&#44; a low-fat diet with adequate calories for weight management&#44; physical exercise and smoking cessation are very effective in all patients and the first step in dealing with atherogenic dyslipidaemia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">&#8211;</span><p id="par0200" class="elsevierStylePara elsevierViewall">Following lifestyle changes&#44; the first safe and effective treatment employed in cardiovascular prevention is statins&#46;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">&#8211;</span><p id="par0205" class="elsevierStylePara elsevierViewall">Patients with hypertriglyceridaemia and low HDL-C&#44; i&#46;e&#46; those with atherogenic dyslipidaemia&#44; benefit from combined therapy with a statin and fenofibrate&#46;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">&#8211;</span><p id="par0210" class="elsevierStylePara elsevierViewall">The clinical practice guidelines and European Medicines Agency advocate fenofibrate plus a statin for the treatment of mixed hyperlipidaemia when TG and HDL-C levels are not adequately controlled&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">&#8211;</span><p id="par0215" class="elsevierStylePara elsevierViewall">Evidence of the clinical benefit and safety of the statin-fenofibrate combination is robust&#46; Combining both drugs in a single tablet simplifies the dosage and may facilitate compliance in the long term&#46;</p></li></ul></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Ethical disclosures</span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Protection of human and animal subjects</span><p id="par0220" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were conducted on human beings or animals for this research&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Confidentiality of data</span><p id="par0225" class="elsevierStylePara elsevierViewall">The authors declare that no patient data is contained in this article&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Right to privacy and informed consent</span><p id="par0230" class="elsevierStylePara elsevierViewall">The authors declare that no patient data is contained in this article&#46;</p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of interest</span><p id="par0235" class="elsevierStylePara elsevierViewall">There is no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres823172"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec819851"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres823171"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec819852"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Definition of atherogenic dyslipidaemia"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Diagnosis"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Cardiovascular risk and therapeutic targets"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Points of consensus in the clinical assessment of atherogenic dyslipidaemia"
        ]
        8 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Treatment of atherogenic dyslipidaemia"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Lifestyle changes"
            ]
            1 => array:3 [
              "identificador" => "sec0035"
              "titulo" => "Pharmacological treatment"
              "secciones" => array:3 [
                0 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Statins"
                ]
                1 => array:2 [
                  "identificador" => "sec0045"
                  "titulo" => "Fibrates"
                ]
                2 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Extralipid effects of fenofibrate"
                ]
              ]
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Points of consensus in the treatment of atherogenic dyslipidaemia"
        ]
        10 => array:3 [
          "identificador" => "sec0060"
          "titulo" => "Ethical disclosures"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Protection of human and animal subjects"
            ]
            1 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Confidentiality of data"
            ]
            2 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        11 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Conflicts of interest"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec819851"
          "palabras" => array:3 [
            0 => "Atherogenic dyslipidaemia"
            1 => "Hypertriglyceridemia"
            2 => "Cardiovascular risk"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec819852"
          "palabras" => array:3 [
            0 => "Dislipemia aterog&#233;nica"
            1 => "Hipertrigliceridemia"
            2 => "Riesgo cardiovascular"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia of the Spanish Society of Arteriosclerosis and by the European Society of Arteriosclerosis&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Documento de posicionamiento y resumen de las recomendaciones recientemente publicadas por el Grupo de Trabajo de Dislipemia Aterog&#233;nica de la Sociedad Espa&#241;ola de Arteriosclerosis y por la Sociedad Europea de Arteriosclerosis&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Ascaso JF&#44; Mill&#225;n J&#44; Hern&#225;ndez-Mijares A&#44; Blasco M&#44; Brea A&#44; D&#237;az &#193;&#44; et al&#46; Documento de consenso sobre el manejo de la dislipemia aterog&#233;nica de la Sociedad Espa&#241;ola de Arteriosclerosis&#46; Clin Invest Arterioscler&#46; 2017&#59;29&#58;86&#8211;91&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1455
            "Ancho" => 2663
            "Tamanyo" => 176493
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Atherogenic dyslipidaemia treatment algorithm&#46; Non-HDL-C&#58; non-HDL cholesterol &#40;total cholesterol minus HDL cholesterol&#41;&#59; HDL-C&#58; high-density lipoprotein cholesterol&#59; CV&#58; cardiovascular&#59; TG&#58; triglycerides&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">HDL-C&#58; high-density lipoprotein cholesterol&#59; LDL-C&#58; low-density lipoprotein cholesterol&#59; TC&#58; total cholesterol&#59; M&#58; men&#59; LDL&#58; low-density lipoproteins&#59; W&#58; women&#59; TG&#58; triglycerides&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#62;150<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HDLc&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;40<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in M and &#60;45<span class="elsevierStyleHsp" style=""></span>mg&#47;dl in W&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">LDLc&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#62;100<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Non-HDL-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#62;130<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TC&#47;HDL-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#62;5 in M and &#62;4&#46;5 in W&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Small and dense LDL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">TG&#47;HDL-C<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1384032.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Atherogenic dyslipidaemia&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">HDL-C&#58; high-density lipoprotein cholesterol&#59; non-HDL-C&#58; cholesterol bound to atherogenic lipoproteins &#40;total cholesterol minus high-density lipoprotein cholesterol&#41;&#59; CV&#58; cardiovascular&#59; CVRF&#58; cardiovascular risk factor&#59; M&#58; men&#59; W&#58; women&#59; TG&#58; triglycerides&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Primary&#58; non-HDL-C</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Moderate CV risk &#40;rare situations&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;145<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>High CV risk&#58; abdominal obesity&#44; metabolic syndrome&#44; CVRF association&#44; diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;130<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Very high CV risk&#58; cardiovascular disease&#44; type 2 diabetes with target organ damage or serious CVRF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;100<span class="elsevierStyleHsp" style=""></span>mg&#47;dl&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Secondary&#58; TG and HDL-C</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>After achieving the primary target&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">TG<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>mg&#47;dl<br>HDL-C<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>40<span class="elsevierStyleHsp" style=""></span>mg&#47;dl M&#44; &#62;45<span class="elsevierStyleHsp" style=""></span>mg&#47;dl W&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1384033.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Lipid targets in atherogenic dyslipidaemia&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">apoA-I&#58; apolipoprotein A-I&#59; apoA-II&#58; apolipoprotein A-II&#59; apoA-V&#58; apolipoprotein A-V&#59; apoC-III&#58; apolipoprotein C-III&#59; CETP&#58; cholesteryl ester transfer protein&#59; HDL&#58; high-density lipoproteins&#59; LDL&#58; low-density lipoproteins&#59; LPL&#58; lipoprotein lipase&#59; TG&#58; triglycerides&#59; VLDL&#58; very low-density lipoproteins&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleBold">Mechanisms</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">TG reduction</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Increases lipolysis &#40;increases LPL activity and apoA-V synthesis&#59; decreases apoC-III synthesis&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Increases plasma clearance of TG-rich lipoproteins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Reduces the availability of fatty acids &#40;decreasing <span class="elsevierStyleItalic">de novo</span> synthesis and increasing oxidation&#41;&#44; and thus TG and VLDL synthesis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Increase in HDL</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Increases apoA-I and apoA-II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Reduces CETP activity&#44; and thus the transfer of cholesterol to VLDL and TG to HDL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Phenotype changes in LDL particles</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Induces a change in small and dense LDL particles &#40;especially atherogenic&#41; to larger and lower-density particles&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1384034.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Lipid effects of fibrates&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">HDL-C&#58; high-density lipoprotein cholesterol&#59; LDL-C&#58; low-density lipoprotein cholesterol&#59; non-HDL-C&#58; cholesterol bound to atherogenic lipoproteins &#40;total cholesterol minus high-density lipoprotein cholesterol&#41;&#59; CVD&#58; cardiovascular disease&#59; TG&#58; triglycerides&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Consider treatment with fibrates for primary CVD prevention in patients with a high cardiovascular risk and for secondary prevention in those with atherogenic dyslipidaemia who present normal LDL-C or non-HDL-C&#44; in general following treatment with a statin&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Class B evidence&#46; Recommendation IIb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">In a diabetic patient undergoing treatment with statins&#44; both in primary and secondary prevention&#44; fenofibrate will be employed if TG levels are above 200<span class="elsevierStyleHsp" style=""></span>mg&#47;dl with or without low HDL-C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Class B evidence&#46; Recommendation IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">The fenofibrate-statin combination is the safest among the fibrate-stain combinations available&#44; due to the low probability of serious adverse events&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Class A evidence&#46; Recommendation IIa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Fenofibrate induces changes in the size of LDL and HDL particles&#44; improves endothelial function&#44; has anti-inflammatory effects&#44; reduces thrombogenesis and plays a protective role in diabetic retinopathy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Class C evidence&#46; Recommendation&#58; consider in the use thereof&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1384035.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Evidence of treatment with fibrates&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:23 [
            0 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of dyslipidemia in the metabolic syndrome&#58; recommendations of the Spanish HDL-Forum"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Ascaso"
                            1 => "P&#46; Gonz&#225;lez Santos"
                            2 => "A&#46; Hern&#225;ndez Mijares"
                            3 => "A&#46; Mangas Rojas"
                            4 => "L&#46; Masana"
                            5 => "J&#46; Mill&#225;n"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Cardiovasc Drugs"
                        "fecha" => "2007"
                        "volumen" => "7"
                        "paginaInicial" => "39"
                        "paginaFinal" => "58"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17355165"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Encuesta Nacional de Salud 2011&#47;2012&#46; Ministerio de Sanidad&#44; Servicios Sociales e Igualdad&#46; Available from <a href="http://www.msssi.gob.es/estadEstudios/estadisticas/encuestaNacional/encuesta2011.htm">http&#58;&#47;&#47;www&#46;msssi&#46;gob&#46;es&#47;estadEstudios&#47;estadisticas&#47;encuestaNacional&#47;encuesta2011&#46;htm</a> &#91;accessed 20&#46;12&#46;16&#93;"
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of diabetes mellitus and impaired glucose regulation in Spain&#58; the Di&#64;bet&#46;es study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Soriguer"
                            1 => "A&#46; Goday"
                            2 => "A&#46; Bosch-Comas"
                            3 => "E&#46; Bordi&#250;"
                            4 => "A&#46; Calle-Pascual"
                            5 => "R&#46; Carmena"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00125-011-2336-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetologia"
                        "fecha" => "2012"
                        "volumen" => "55"
                        "paginaInicial" => "88"
                        "paginaFinal" => "93"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21987347"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes&#58; a cross-sectional study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46; Valensi"
                            1 => "A&#46; Avignon"
                            2 => "A&#46; Sultan"
                            3 => "B&#46; Chanu"
                            4 => "M&#46;T&#46; Nguyen"
                            5 => "E&#46; Cosson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s12933-016-0415-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cardiovasc Diabetol"
                        "fecha" => "2016"
                        "volumen" => "15"
                        "paginaInicial" => "104"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27450534"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dislipemia aterog&#233;nica y riesgo residual&#46; Estado de la cuesti&#243;n en 2014"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Residual Risk Reduction Initiative y Grupo de Trabajo sobre dislipemia aterog&#233;nica"
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Mill&#225;n N&#250;&#241;ez-Cortes"
                            1 => "J&#46; Pedro-Botet Montoya"
                            2 => "J&#46; Pint&#243; Sala"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscl"
                        "fecha" => "2014"
                        "volumen" => "26"
                        "paginaInicial" => "287"
                        "paginaFinal" => "292"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lipoprotein ratios&#58; physiological significance and clinical usefulness in cardiovascular prevention"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Mill&#225;n"
                            1 => "X&#46; Pint&#243;"
                            2 => "A&#46; Mu&#241;oz"
                            3 => "M&#46; Z&#250;&#241;iga"
                            4 => "J&#46; Rubi&#233;s-Prat"
                            5 => "L&#46;F&#46; Pallardo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Vasc Health Risk Manag"
                        "fecha" => "2009"
                        "volumen" => "5"
                        "paginaInicial" => "757"
                        "paginaFinal" => "765"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19774217"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Importancia de la dislipemia en la enfermedad cardiovascular&#58; un punto de vista"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;F&#46; Ascaso"
                            1 => "R&#46; Carmena"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscler"
                        "fecha" => "2015"
                        "volumen" => "27"
                        "paginaInicial" => "301"
                        "paginaFinal" => "308"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46; Andersson"
                            1 => "A&#46; Lyass"
                            2 => "R&#46;S&#46; Vasan"
                            3 => "J&#46;M&#46; Massaro"
                            4 => "R&#46;B&#46; d&#8217;Agostino"
                            5 => "S&#46;J&#46; Robins"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ahj.2014.08.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Heart J"
                        "fecha" => "2014"
                        "volumen" => "168"
                        "paginaInicial" => "878"
                        "paginaFinal" => "883"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25458651"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Association of LDL cholesterol&#44; non-HDL cholesterol&#44; and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins&#58; a meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;M&#46; Boekholdt"
                            1 => "B&#46;J&#46; Arsenault"
                            2 => "S&#46; Mora"
                            3 => "T&#46;R&#46; Pedersen"
                            4 => "J&#46;C&#46; LaRosa"
                            5 => "P&#46;J&#46; Nestel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.2012.366"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2012"
                        "volumen" => "307"
                        "paginaInicial" => "1302"
                        "paginaFinal" => "1309"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22453571"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-HDL cholesterol and triglycerides&#58; implications for coronary atheroma progression and clinical events"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Puri"
                            1 => "S&#46;E&#46; Nissen"
                            2 => "M&#46; Shao"
                            3 => "M&#46;B&#46; Elshazly"
                            4 => "Y&#46; Kataoka"
                            5 => "S&#46;R&#46; Kapadia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/ATVBAHA.116.307601"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arterioscler Thromb Vasc Biol"
                        "fecha" => "2016"
                        "volumen" => "36"
                        "paginaInicial" => "2220"
                        "paginaFinal" => "2228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27515380"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consenso sobre tratamiento farmacol&#243;gico de la dislipidemia aterog&#233;nica con terapia combinada estatina-fenofibrato"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "Panel Europeo de Expertos&#46; Versi&#243;n espa&#241;ola del Grupo de Trabajo sobre Dislipemia Aterog&#233;nica"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscler"
                        "fecha" => "2016"
                        "volumen" => "28"
                        "paginaInicial" => "87"
                        "paginaFinal" => "93"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "La aut&#233;ntica dimensi&#243;n del colesterol-no-HDL&#58; colesterol aterog&#233;nico"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Grupo de trabajo sobre Dislipemia Aterog&#233;nica&#46; Sociedad Espa&#241;ola de Arteriosclerosis"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Mill&#225;n"
                            1 => "A&#46; Hern&#225;ndez-Mijares"
                            2 => "J&#46;F&#46; Ascaso"
                            3 => "M&#46; Blasco"
                            4 => "A&#46; Brea"
                            5 => "A&#46; D&#237;az"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscler"
                        "fecha" => "2016"
                        "volumen" => "28"
                        "paginaInicial" => "265"
                        "paginaFinal" => "270"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Metabolic syndrome&#58; a marker of patients at high cardiovascular risk"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46;C&#46; Lau"
                            1 => "H&#46; Yan"
                            2 => "B&#46; Dhillon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Can J Cardiol"
                        "fecha" => "2006"
                        "volumen" => "22"
                        "numero" => "Suppl&#46; B"
                        "paginaInicial" => "85B"
                        "paginaFinal" => "90B"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16498518"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2016 European Guidelines on cardiovascular disease prevention in clinical practice&#58; The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;F&#46; Piepoli"
                            1 => "A&#46;W&#46; Hoes"
                            2 => "S&#46; Agewall"
                            3 => "C&#46; Albus"
                            4 => "C&#46; Brotons"
                            5 => "A&#46;L&#46; Catapano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2315"
                        "paginaFinal" => "2381"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2016 ESC&#47;EAS guidelines for the management of dyslipidaemias"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology &#40;ESC&#41; and European Atherosclerosis Society &#40;EAS&#41;"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Catapano"
                            1 => "I&#46; Graham"
                            2 => "G&#46; de Backer"
                            3 => "O&#46; Wiklund"
                            4 => "M&#46;J&#46; Chapman"
                            5 => "H&#46; Drexel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw272"
                      "Revista" => array:3 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27141094"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atherogenic dyslipidemia&#58; prevalence and management in lipid clinics"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "en nombre del grupo de investigadores EDICONDIS-ULISEA"
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Pedro-Botet"
                            1 => "J&#46;A&#46; Flores-le Roux"
                            2 => "J&#46;M&#46; Mostaza"
                            3 => "X&#46; Pint&#243;"
                            4 => "J&#46;J&#46; de la Cruz"
                            5 => "J&#46;R&#46; Banegas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rce.2014.06.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Clin Esp"
                        "fecha" => "2014"
                        "volumen" => "214"
                        "paginaInicial" => "491"
                        "paginaFinal" => "498"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25016414"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of cholesterol-lowering treatment&#58; prospective meta-analysis of data from 90&#44;056 participants in 14 randomised trials of statins"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Cholesterol Treatment Trialists&#8217; &#40;CTT&#41; Collaborators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Baigent"
                            1 => "A&#46; Keech"
                            2 => "P&#46;M&#46; Kearney"
                            3 => "L&#46; Blackwell"
                            4 => "G&#46; Buck"
                            5 => "C&#46; Pollicino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67394-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1267"
                        "paginaFinal" => "1278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214597"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of statins for primary prevention in people at low cardiovascular risk&#58; a meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Tonelli"
                            1 => "A&#46; Lloyd"
                            2 => "F&#46; Clement"
                            3 => "J&#46; Conly"
                            4 => "D&#46; Husereau"
                            5 => "B&#46; Hemmelgarn"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1503/cmaj.101280"
                      "Revista" => array:6 [
                        "tituloSerie" => "CMAJ"
                        "fecha" => "2011"
                        "volumen" => "183"
                        "paginaInicial" => "E1189"
                        "paginaFinal" => "E1220"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21989464"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "HDL cholesterol&#44; very low levels of LDL cholesterol&#44; and cardiovascular events"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46; Barter"
                            1 => "A&#46;M&#46; Gotto"
                            2 => "J&#46;C&#46; LaRosa"
                            3 => "J&#46; Maroni"
                            4 => "M&#46; Szarek"
                            5 => "S&#46;M&#46; Grundy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa064278"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2007"
                        "volumen" => "357"
                        "paginaInicial" => "1301"
                        "paginaFinal" => "1310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17898099"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of combination lipid therapy in type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "ACCORD Study Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;N&#46; Ginsberg"
                            1 => "M&#46;B&#46; Elam"
                            2 => "L&#46;C&#46; Lovato"
                            3 => "J&#46;R&#46; Crouse 3rd"
                            4 => "L&#46;A&#46; Leiter"
                            5 => "P&#46; Linz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1001282"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2010"
                        "volumen" => "362"
                        "paginaInicial" => "1563"
                        "paginaFinal" => "1574"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20228404"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Implications of the ACCORD lipid study&#58; perspective from the Residual Risk Reduction initiative &#40;R<span class="elsevierStyleSup">3</span>i&#41;"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "International Steering Committee of R<span class="elsevierStyleSup">3</span>i"
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;C&#46; Fruchart"
                            1 => "F&#46;M&#46; Sacks"
                            2 => "M&#46;P&#46; Hermans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1185/03007995.2010.489341"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Med Res Opin"
                        "fecha" => "2010"
                        "volumen" => "26"
                        "paginaInicial" => "1793"
                        "paginaFinal" => "1797"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20482323"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current practice in identifying and treating cardiovascular risk&#44; with a focus on residual risk associated with atherogenic dyslipidaemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Ferrari"
                            1 => "C&#46; Aguiar"
                            2 => "E&#46; Alegria"
                            3 => "R&#46;C&#46; Bonadonna"
                            4 => "F&#46; Cosentino"
                            5 => "M&#46; Elisaf"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "18"
                        "numero" => "Suppl&#46; C"
                        "paginaInicial" => "C2"
                        "paginaFinal" => "C12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9152669"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Terapia con fibratos&#58; uso racional del fenofibrato 2016&#46; Resumen ejecutivo"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "en nombre del Foro de la Dislipemia Aterog&#233;nica"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Brea"
                            1 => "J&#46; Mill&#225;n"
                            2 => "J&#46;F&#46; Ascaso"
                            3 => "M&#46; Blasco"
                            4 => "A&#46; D&#237;az"
                            5 => "P&#46; Gonz&#225;lez-Santos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Invest Arterioscler"
                        "fecha" => "2016"
                        "volumen" => "28"
                        "paginaInicial" => "295"
                        "paginaFinal" => "301"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/25299123/0000002900000002/v1_201704010059/S2529912317000183/v1_201704010059/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "64743"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Consensus Statement"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/25299123/0000002900000002/v1_201704010059/S2529912317000183/v1_201704010059/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912317000183?idApp=UINPBA00004N"
]
Article information
ISSN: 25299123
Original language: English
DOI:10.1016/j.artere.2016.11.001
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 5 1 6
2024 October 12 5 17
2024 September 20 15 35
2024 August 18 8 26
2024 July 15 2 17
2024 June 14 4 18
2024 May 10 3 13
2024 April 21 4 25
2024 March 25 3 28
2024 February 13 7 20
2024 January 19 4 23
2023 December 10 10 20
2023 November 22 7 29
2023 October 30 8 38
2023 September 30 6 36
2023 August 11 6 17
2023 July 14 9 23
2023 June 26 8 34
2023 May 34 10 44
2023 April 39 15 54
2023 March 33 4 37
2023 February 25 11 36
2023 January 24 5 29
2022 December 25 7 32
2022 November 24 9 33
2022 October 23 5 28
2022 September 31 7 38
2022 August 21 10 31
2022 July 17 7 24
2022 June 23 11 34
2022 May 18 10 28
2022 April 19 36 55
2022 March 14 6 20
2022 February 40 7 47
2018 April 19 0 19
2018 March 7 1 8
Show all

Follow this link to access the full text of the article

Subscribe to our newsletter

Publish in
Clínica e Investigación en Arteriosclerosis
Highlighted articles
Free access articles
To the family of professor Pedro Valdivielso...
10.1016/j.artere.2024.10.002
Prof. Rafael Carmena...
Clin Investig Arterioscler. 2024;36:267-8
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos